Abstract-Disruption of the blood-brain barrier (BBB) and subsequent neurological deficits are the most severe consequence of intracerebral hemorrhage (ICH). Minocycline has been wildly used clinically as a neurological protective agent in clinical practice. However, the underlying mechanisms by which minocycline functions remain unclear. Therefore, we assessed the influence of minocycline on BBB structure, neurological function, and inflammatory responses in a collagenase-induced ICH model, and elucidated underlying molecular mechanisms as well. Following a single injection of collagenase VII-S into the basal ganglia, BBB integrity was assessed by Evans blue extravasation while neurological function was assessed using an established neurologic function scoring system. Minocycline treatment significantly alleviated the severity of BBB disruption, brain edema, and neurological deficits in ICH model. Moreover, minocycline decreased the production of inflammatory mediators including TNF, IL-6, and MMP-9, by microglia. Minocycline treatment decreased DKK1 expression but increased Wnt1, β-catenin and Occludin, a phenomenon mimicked by DKK1 silencing. These data suggest that minocycline improves the consequences of ICH by preserving BBB integrity and attenuating neurologic deficits in a DKK1-related manner that involves enhancement of the Wnt1-β-catenin activity.
INTRODUCTION
Intracerebral hemorrhage (ICH) is a significant cause of morbidity and mortality throughout the world (Flaherty et al., 2006) . However, due to the limited mechanistic insight, precision targeted therapies and an effective drug to improve the ICH outcomes are urgently required. Following ICH, perihematomal edema develops within 3 h from the onset of symptoms, peaking between 10 and 20 days post-ictus (Xi, Keep, and Hoff, 2006; Zazulia, Diringer, Derdeyn, and Powers, 1999) . Brain edema is a critical factor in the subsequent development of neurologic deficits by increasing intracranial pressure or by causing a substantial midline shift (Wasserman and Schlichter, 2007a) . While multiple forms of edema develop after ICH, the primary type is vasogenic cerebral edema resulting from an increase in permeability of blood-brain barrier (BBB) (Xi et al., 2006) .
Minocycline (Mino) is a second-generation, semisynthetic tetracycline derivative with established antimicrobial effects and inhibition of microglial activation (Ryu, Franciosi, Sattayaprasert, Kim, and McLarnon, 2004; Tikka and Koistinaho, 2001; Wasserman and Schlichter, 2007a; Wasserman and Schlichter, 2007b) . During the last 20 years, Mino has been wildly used clinically as a neuroprotective agent (Stirling, Koochesfahani, Steeves, and Tetzlaff, 2005; Yong et al., 2004) . Due to high lipophilicity and tissue penetration, Mino could easily penetrate the BBB (Klein and Cunha, 1995) . However, although there are many studies focused on the physiological property and the protective role of this chemical, the underlying molecular mechanism that Mino protects the integrity of BBB and reduces brain edema remains poorly elucidated, especially in the progression of ICH. Wnt/β-catenin signaling has been demonstrated to protect against the edema of BBB and control the expression of multiple downstream targets such as Occludin (Liebner et al., 2008; Nakamura, Si, and Kataoka, 1999; Ramirez et al., 2013; Wang et al., 2007) . In contrast, inhibition of Wnt/β-catenin activity has been reported to enhance the production of inflammatory mediators (Duan et al., 2007; Wang et al., 2016) , thus progressing ICH. Dickkopf-1 (DKK1) is a major upstream suppressor of Wnt/β-catenin signaling pathway (Zhuang et al., 2017) . Inhibition or deficiency of DKK1 enhances Wnt signaling activity and subsequent increases the expression of β-catenin (Duan et al., 2017) . Our previous study found that siRNA mediated DKK1 deficiency could significantly alleviate ICH-induced brain damage (Li et al., 2017a) , indicating Wnt/β-catenin signaling may play a protective role in the progression of ICH. Although the protective effect of Mino on the integrity of BBB and its influences on a variety of signaling pathways including PI3K, MAPK, and NF-κB (Garrido-Mesa, Zarzuelo, and Galvez, 2013; Jordan et al., 2007) , have been widely reported, it is still not known if Mino protects against the brain damage in ICH and the consequences of Mino delivery on the DKK1-Wnt signaling axis remain to be ascertained.
Therefore, we examined the effects of Mino on the expression of DKK1 and the activity of Wnt/β-catenin signaling, and on BBB integrity, brain edema and neurological dysfunction in a collagenase-induced ICH rat model and in cultured microglia. We also examined the influences of Mino on the production of inflammatory mediators in microglia. Thus, we established, for the first time, that Mino protects against ICH neurological damage, at least in part, through inhibition of DKK1 and the subsequent activation of Wnt-β-cateninOccludin signaling axis. Establishment of this neuroprotective mechanism may facilitate the development of more precise interventional strategies for patients with ICH.
EXPERIMENTAL PROCEDURES
All the experimental protocols in this study were in accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals, formulated by the Ministry of Science and Technology of China.
Animals and study design
A total of 225 adult male Sprague-Dawley rats (280-300 g; 8-10 weeks old) were purchased from the Experimental Animal Center of Henan Province. The rats were housed under conditions of constant temperature, humidity, and a 12/12-h light/dark cycle, with food and water available. Rats were randomly assigned into six groups: 1) Sham: rats that were treated with needle insertion only; 2) ICH + vehicle: rats that underwent ICH induction and intraperitoneal injection of saline; 3) ICH + scramble siRNA (siNC): rats that underwent ICH induction and intraventricular injection of siNC; 4) ICH + siDKK1: rats that underwent ICH induction and intraventricular injection of siDKK1; 5) ICH + Mino: rats that underwent ICH induction and intraperitoneal injection of Mino; 6) ICH + siDKK1 + Mino: rats that underwent ICH induction and intraventricular injection of siDKK1 plus intraperitoneal injection of Mino. Animals that died or were euthanized were excluded from the sample size. Outlying data points were defined with statistical software assuming a normal distribution (threshold was set as 2.0-fold of SD from the mean) and were excluded from the dataset. Animals for each group were randomized with the website (www.randomization.com). Treatment, data collection, and data analyses were blinded by using different investigators or by masking sample labels.
ICH rat model and microglia
The time-line of the study design was shown in Fig. 1 . After anesthesia with pentobarbital (45 mg/kg, i.p.), rats were positioned on a stereotaxic frame (Stoelting Co., Wood Dale, IL, USA). An incision was made on the skin along the sagittal midline to expose the skull. A burr hole (1 mm) was drilled 3.5 mm lateral, 0.2 mm anterior to the bregma and 5.5 mm deep, then collagenase VII-S (sterile-filtered, 0.5 U in 0.5 μl sterile saline, Sigma, St. Louis, MO, USA) was injected into the right basal ganglia of rats at the following stereotactic coordinates: 0.2 mm anterior and 3.5 mm lateral of the bregma, and 5.5 mm in depth. The needle was left for an additional 10 min and withdrawn slowly (at a rate of 1 mm/ min) to minimize backflow of the infused collagenase solution along the needle track. The burr hole was sealed with bone wax, the skin was sutured and rats were allowed to recover under observation. The core temperature of the animals was maintained at 37.0 ± 0.5°C with a heating pad throughout the experimental and recovery periods. For the sham control rats, a burr hole was drilled at the same position but without collagenase injection. Rats that died before the end of the study were excluded; otherwise, all animals proceeded into the final analysis. Immortalized rat microglia were purchased from Applied Biological Material (Richmond, BC, Canada; Cat. TM0246), and cultured with high glucose DMEM medium supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 20 mM HEPES, 50 U/ml penicillin and 50 μg/ml streptomycin in an incubator with 5% CO 2 and 37°C. 4 × 10 5 cells were plated in the 12-well plate and then challenged with E. coli LPS (100 ng/ml; Invivogen, USA) with or without the pretreatment of Mino with various concentrations (1 μg/ml; 10 μg/ml; and 50 μg/ml). Then, the cell-free supernatant was collected for the assay of inflammatory mediators, and whole cell lysates were harvested after 4-h challenge with LPS to analyze the expression of DKK1, β-catenin, and GAPDH.
Drug and siRNA administration
Mino was dissolved in saline, which was injected intraperitoneally (i.p.) at dose of 45 mg/kg immediately and 12 h after ICH, followed by 22.5 mg/kg twice a day for 2 days. In the control group, rats received saline only. For in vivo small interfering RNA (siRNA) administration, DKK1 small interfering RNA (siDKK1), as well as negative control siRNA (siNC) (GenePharma, Shanghai, China), was dissolved in sterile RNase-free water according to the manufacturer's instructions. The siRNA sequences targeting DKK1 are as follows: sense: 5′-GCGUGGGAGGUGUACAAAU-3′; antisense: 5′-AUUUGUACACCUCCCACGC-3′. The negative control siRNA sequences are: sense5′-UUCUCCGAACGU GUCACGU-3′; antisense 5′-ACGUGACACGUUCGGA GAA-3′. All these siRNAs were administered via intracerebroventricular (i.c.v.) injection 48 h prior to ICH-induction, as previously described (Li Z, et al., 2017) .
Brain water content examination and Evans blue analysis
At 1, 3 and 7 days after ICH induction, we measured brain water content as a reflection for brain edema. Animals were anesthetized with pentobarbital (60 mg/kg, i.p.), and the brain was removed quickly. The brains were dissected into the ipsilateral and contralateral cortex, the ipsilateral and contralateral basal ganglia, and the cerebellum, which served as an internal control. Brain samples were weighed immediately after harvesting on a precise electronic balance (model AE 100; Mettler Instrument Corp., Hightstown, NJ) to determine the wet weight. Brain samples were then dried at 100°C for 24 h to determine the dry weight and brain water content calculated as [(wet weight − dry weight) / wet weight] × 100%. The integrity of the BBB was investigated by measuring the extravasation of Evans blue (EB). Evans blue dye (2% in saline, 4 ml/kg) was injected via the tail vein at 1, 3 and 7 days after ICH. Two hours later, the rats were perfused with 0.1 M phosphate-buffered saline (PBS) to wash out any remaining dye in the blood vessels. After decapitation, the brain was removed and dissected into left and right hemispheres and each hemisphere was weighed. The brain samples were homogenized in 1100 μl of PBS, sonicated and centrifuged (10,000 rpm for 20 min) separately. 50% trichloroacetic acid (500 μl) was added to 500 μl of the supernatant layer and incubated overnight at 4°C. The supernatant was measured at 610 nm for absorbance using a spectrophotometer (Ultrospec 3; Pharmacia LKB). The tissue content of Evans blue was quantified from a linear standard curve and was expressed as micrograms per gram of brain tissue. And the results were shown by the ratio of ipsi-/contra-brain EB content.
Western blotting and ELISA
The brain tissues were sampled 1 mm away from the hematoma to avoid potential red blood cell contamination as previously described (Guo, Hua, Wang, Keep, and Xi, 2012) . We homogenized tissues in ice-cold protein extraction reagent and total protein was quantified by BCA protein assay (Solarbio, catalog: PC0020). Equal amounts of protein (50 μg) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and blotted to polyvinylidene fluoride (PVDF) membranes. Then, the membranes were probed with primary antibodies against DKK1 (Abcam, catalog: ab109416; 1:1000), Wnt1 (Abcam, catalog: ab85060; 1:1000), β-catenin (Abcam, catalog ab32572; 1:5000), Occludin (Abcam, catalog: ab216327; 1:1000) and GAPDH (Proteintech, catalog: 10494-1-AP; 1:2000) at 4°C overnight. After incubation with goat antirabbit secondary antibodies (Jackson ImmunoResearch, catalog: 111-035-003; 1:10000) for 2 h, the blots were immersed in enhanced chemiluminescence (ECL) solution (Solarbio, catalog: PE0010) and exposed under an ImageQuant ECL Imager. The relative intensity of protein signals was normalized to the corresponding loading control intensity and quantified by densitometric analysis with ImageJ software. 4.0 × 10 5 rat microglia were placed in 12-well plates and treated with E. coli LPS (100 ng/ml) for 24 h, and then the cell-free supernatants were assayed for cytokine and MMP-9 levels by ELISA (eBioscience). For Western blot, the whole cell lysate was collected after 4-h challenge with E. coli LPS and 15μg total protein was used for analysis.
Immunohistochemistry
The immunohistochemistry method has been described previously (Guo et al., 2012) . The rats were anesthetized and perfused with 4% paraformaldehyde in 0.1 M PB (pH 7.4). The brains were removed and kept in 4% paraformaldehyde for 4 h, then immersed in 25% sucrose until sink at 4°C. The brain was sliced into 20-μm-thick sections using a freezing microtome (CM1950, Leica, Heidelberg, Germany). The avidin-biotin complex technique was used in the staining. The sections were sequentially incubated at room temperature with the following: 10% normal donkey serum for 30 min, primary antibody rabbit anti-DKK1 antibody (Abcam, catalog: ab109416; 1:300) for 24 h, peroxidase-conjugated AffiniPure goat anti-rabbit IgG (H + L) (Jackson ImmunoResearch, catalog: 111-035-003; 1:5000) for 6 h, and avidin-biotin-peroxidase complex (ABC) (ABC Elite Kit; 1:200; Vector Laboratories) for another 2 h. Peroxidase activity was revealed by dipping the sections for 5 min in a mixture containing 3-diaminobenzidine (DAB) and H 2 O 2 at room temperature. The sections were dehydrated and coverslipped. 
Immunofluorescence
Rats were perfused with 4% paraformaldehyde after they were anesthetized with isoflurane for the preparation of double-labeled immunohistochemistry. Rats brains were removed, post-fixed, and dehydrated before frozen sectioning at 25 μm. After the sections were blocked for 1-2 h in 0.01 M PBS containing 10% goat serum and 0.3% Triton X-100 at room temperature, they were incubated with the following primary antibodies overnight at 4°C. Further details are provided in the online-only Data Supplement. The antibodies and reagents included rabbit anti-DKK1 (Abcam, catalog: ab109416; 1:200), mouse anti-NeuN (Abcam, catalog: ab104224; 1:300), mouse anti-CD11b/c (Abcam, catalog: ab1211; 1:200), and mouse anti-GFAP (Abcam, catalog: ab10062; 1:200). The sections were then incubated with either goat anti-rabbit antibody conjugated to Cy3 (Abcam, catalog: ab6939; 1:300) or goat antimouse antibody conjugated to FITC (Abcam, catalog: ab6785; 1:500) for 2 h in the incubator at 37°C. All immunofluorescence-stained images were examined using a Leica DMI4000 fluorescence microscope and captured with a DFC365FX camera (Leica, Germany).
Neurologic function evaluations and neurologic deficit score
An experimenter blinded to treatment group evaluated rats for neurologic function after ICH. ICH-induced neurological deficits were assessed using the neurologic deficit scoring system, forelimb placing, forelimb use asymmetry, and corner turn tests (Guo et al., 2012; Hua et al., 2002; Li et al., 2017b) . In the neurologic deficit scoring system, rats were evaluated for body symmetry, gait, climbing, circling behavior, front limb symmetry, and compulsory circling. Each test was graded from 0 to 4, establishing a maximum deficit score of 24 (Li et al., 2017b; Wu et al., 2017) .
Measurement of forelimb placing
In the vibrissae-elicited forelimb placing test, animals were held by their bodies to allow the forelimbs to hang free. Independent testing of each forelimb was conducted by brushing the respective vibrissae on the corner edge of a countertop. Intact animals place the forelimb ipsilateral to the stimulated vibrissae quickly onto the countertop. Depending on the extent of injury, placing of the forelimb contralateral to the injury in response to contralateral vibrissae contact with countertop may be impaired. Each rat was tested 10 times for each forelimb, and the percentage of trials in which the rat placed the appropriate forelimb on the edge of the countertop in response to the vibrissae stimulation was determined.
Forelimb use asymmetry test
Forelimb use during exploratory activity was analyzed in a transparent cylinder for 3 to 10 min depending on the degree of activity during the trial. Behavior was quantified by determining the occasions when the unimpaired (ipsilateral) forelimb was used as a percentage of total number of limb use observations on the wall (I), the occasions when the impaired (contralateral) forelimb was used as a percentage of total number of limb use observations on the wall (C), and the occasions when both forelimbs were used simultaneously (or nearly simultaneously during lateral side-stepping movements) as a percentage of total number of limb use observations on the wall (B). A single overall limb use asymmetry score was calculated as follows: forelimb using asymmetry score = [I / (I + C + B)] − [C / (I + C + B)].
Corner turn test
The rat was allowed to proceed into a corner, the angle of which was 30°. To exit the corner, the rat could turn to either the left or the right, and the direction was recorded. This was repeated 10 times, with at least 30 s between trials, and the percentage of right turns was calculated. Only turns involving full rearing along either wall were included (ventral tucks or horizontal turns were excluded).
Statistics
Parametric data in this study are expressed as mean ± standard deviations. Differences between two groups were determined by two-tailed Student's t-test. One-way ANOVA followed by Bonferroni correction was used to compare differences between multiple groups. Non-parametric tests (Mann-Whitney and Kruskal-Wallis test) were used to compare non-normally distributed experimental data. All analyses were carried out with GraphPad Prism 6.0 Software. P < 0.05 was considered statistically significant.
RESULTS
ICH induces the most severe BBB disruption in basal ganglia at day 3
To understand the extent of ICH-mediated BBB disruption in rat brain, the integrity of the BBB was assessed through the extravasation of Evan's blue. As shown in Fig. 2A , Evan's blue extravasation in basal ganglia is significantly enhanced in the rats that underwent ICH, as compared to controls. ICH induces most significant Evan's blue extravasation in basal ganglia at day 3, compared with that of day 1 and day 7 (2.23 ± 0.29 versus 1.33 ± 0.15 and 1.28 ± 0.15, respectively; P < 0.001; n = 6; Fig. 2B ). Moreover, the brain water content was also measured at different time points. We found that brain water content is also significantly increased in the basal ganglia at day 1 and day 3 after ICH, but not at day 7 (Fig. 2D) . The amount of brain water content is maximized at day 3 after ICH, compared with that of day 1 and day 7 (81.60 ± 0.53 versus 79.30 ± 1.23 and 79.0 ± 1.05%, respectively; P < 0.01; n = 6; Fig. 2C ). These results strongly suggest that ICH causes BBB disruption, which is most severe in basal ganglia at day 3. Since the injury starts to heal after day 3, we investigated the related changes at this time point throughout the following experiments.
Mino reduces BBB disruption after ICH
Mino has been widely used in clinical practice for the control of inflammation responses in central nervous system and other bacterial infection as well. To assess the protective effects of Mino on ICH, we next administer it after the induction of ICH. We find that Evan's blue extravasation in ipsilateral basal ganglia was reduced significantly at day 3 in the group with the treatment of Mino (1.77 ± 0.20 versus 2.19 ± 0.39; P < 0.05; n = 6; Fig. 3A, B) , as compared with the vehicle group. Moreover, the brain water content in the ipsilateral basal ganglia is also attenuated in Mino treated group, as compared to the vehicle control group (80.93 ± 0.76 versus 83.02 ± 0.45%; P < 0.01; n = 6; Fig. 3C ).
These results showed that Mino indeed has protective effects on ICH through attenuating the severity of BBB disruption and the content of brain water.
Mino suppresses the expression of DKK1 and the production of inflammatory mediators in ICH model and microglia
Our previous study has demonstrated that siRNA mediated DKK1 deficiency protected against brain damage in ICH model (Li, Li, Qi, and Yuan, 2015) . To test if treatment of Mino Fig. 2 . The blood-brain barrier permeability and brain edema in rats after intracerebral hemorrhage (ICH). (A) Representative images of the brain tissues staining with Evan's blue at 1, 3 and 7 days after ICH. (B) Blood-brain permeability was evaluated using Evan's blue staining at 1, 3 and 7 days after ICH (n = 6 for each time point; *P < 0.05, **P < 0.01, ***P < 0.001). (C) Brain water content in ipsilateral basal ganglia at 1, 3 and 7 days after ICH (n = 6 for each time point; **P < 0.01). (D) Brain water content in contralateral cortex (Contra-Cortex), ipsilateral cortex (Ipsi-Cortex), contralateral basal ganglia (Contra-Basal Ganglia), ipsilateral basal ganglia (Ipsi-Basal Ganglia), and the cerebellum (Cerebellum) at 1, 3 and 7 days after ICH (n = 6 for each time point; *P < 0.05, **P < 0.01). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) affects the expression of DKK1 and by which protects against ICH-mediated brain damage this hypothesis, we next examine the DKK1 expression and its downstream signaling. We find that the expression of DKK1 is significantly reduced in brain tissues near the hemorrhagic region, as compared to the vehicle control group (0.75 ± 0.19 versus 1.69 ± 0.30; P < 0.01; n = 3; Fig. 4A ). In addition, immunohistochemistry showed the expression of DKK1 remarkably increased after ICH, and this increase was abrogated by the treatment of Mino, which was exactly consistent with our western blot results (Fig. 4B, C) , indicating that Mino led to the suppression of DKK1 which could be the reason for its protective effects on ICH. To further characterize the function of DKK1, we next examine the localization of DKK1 in perihematomal tissues through fluorescence staining with multiple molecular markers including CD11b/c, NeuN, and GFAP. Fascinatingly, we find the DKK1 is co-localized with the CD11b/c-or NeuN-positive cells, but not GFAP cells (Fig. 4D) . Since CD11b/c is mainly expressed in myeloid-derived immune cells such as activated microglia, we next utilize rat microglia as a model to examine the influences of Mino on the expression of DKK1 and the production of inflammatory mediators. As shown in Fig. 5D , Mino robustly decreases the expression of DKK1, while substantially increasing the expression of β-catenin, as compared with control. To further examine the anti-inflammatory effects of Mino, a prototypical agonist of TLR4, E. coli LPS, was used to challenge microglial cells in the presence and absence of Mino. We found that Mino pretreatment significantly decreases the production of LPSinduced TNF, IL-6 and MMP-9 in microglia (Fig. 5A to C) . Considering the anti-inflammatory and protective function of β-catenin in different animal models (Gao, Wang, Peng, and Deng, 2019; Koch et al., 2011; Manicassamy et al., 2010) , these results suggest that Mino could reduce the production of inflammatory mediators through down-regulating DKK1 and subsequently enhancing the expression of β-catenin.
Mino enhances the expression of downstream molecules of DKK1 signaling including Wnt1, β-catenin and Occludin
To confirm the influences of Mino on the activation of DKK1 signaling, we next examine the expression of DKK1 downstream molecules including Wnt1, β-catenin and Occludin in perihematomal tissues. As shown in Fig. 6B , Mino significantly enhanced the protein levels of Wnt1, β-catenin and Occludin, as compared to the vehicle group (Wnt1: P < 0.01; β-catenin: P < 0.01; Occludin: P < 0.05; Fig. 6B ), suggesting that Mino indeed affected the activation of DKK1 and its downstream molecules. To explore the possible association between Mino and DKK1, siRNA was used to silence total DKK1 (Fig. 6A) , and then we examine the expression of other downstream molecules. We found that deficiency of DKK1 significantly enhanced the expression of Wnt1, β-catenin and Occludin, as compared with the ICH only control group (Wnt1: P < 0.01; β-catenin: Fig. 3 . Mino reduces blood-brain barrier permeability and brain edema in rats after intracerebral hemorrhage (ICH). (A) Morphology of brain tissues is shown to observe the effects of Mino on reduction of Evan's blue extravasation at 3 days after ICH. (B) Blood-brain permeability was evaluated using Evan's blue staining at 3 days after ICH (n = 6 for each group; *P < 0.05, ***P < 0.001). (C) Brain water content in contralateral cortex (Contra-Cortex), ipsilateral cortex (Ipsi-Cortex), contralateral basal ganglia (Contra-Basal Ganglia), ipsilateral basal ganglia (IpsiBasal Ganglia), and the cerebellum (Cerebellum) at 3 days after ICH (n = 6 for each group; **P < 0.01, ***P < 0.001). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) P < 0.01; Occludin: P < 0.05; Fig. 6B ). Moreover, deficiency of DKK1 combined with treatment of Mino exhibited synergistic effects compared with treatment with either of them (Wnt1: P < 0.05; β-catenin: P < 0.05; Occludin: P < 0.01; Fig. 6B ). In addition, we also assessed the effects of Mino and siRNAmediated deficiency of DKK1 on the integrity and permeability of BBB. We found that treatment with Mino significantly reduced Evan's blue extravasation and brain water content, as compared to the vehicle only group (both P < 0.05; Fig. 6C, D) . Moreover, a combined treatment with Mino and DKK1 siRNA led to a significantly more reduction of Evan's blue extravasation and brain water content than either treatment used alone (both P < 0.05 versus ICH + Mino group; Fig. 6C, D) . These results suggest that decrease of DKK1 is indeed a protective factor for brain damage. In addition, neurologic deficits examination at 3 days after ICH showed that treatment with Mino or siRNA of DKK1 significantly attenuates the neurologic deficits, including significant improvements in corner turn test, forelimb placing score, and forelimb using asymmetry score, as compared to the vehicle-treated ICH rats (all P < 0.05; Fig. 7) , indicating the protective function of Mino or DKK1 inhibition in ICH.
DISCUSSION
The molecular mechanisms by which Mino protects against brain damage remain unclear. Here, we utilized ICH model to investigate the protective effects of Mino on brain damage and delineated the signaling pathway Mino may employ in this process. Mino decreases the expression of DKK1 and activates Wnt/β-catenin signaling, elevates the expression of Occludin, and reduces the production of inflammatory mediators and MMP-9 in perihematomal tissue and rat microglia. These findings established that Mino acts through DKK1-Wnt-Occludin signaling to protect against brain damage in ICH, indicating the inhibition of DKK1 and/or the activation of Wnt signaling pathway could be a precise interventional strategy for the improvement of brain damage in ICH (Fig. 8) .
Disruption of BBB integrity and subsequent increased permeability are the major aspects of brain injury after ICH. BBB injury results in the formation of brain edema and swelling, the increased intracranial pressure, and the shift of the midline, and ultimately aggravates the outcomes of ICH (Xi et al., 2006; Yang, Betz, Chenevert, Brunberg, and Hoff, 1994 ). In the model we used here, both BBB disruption and brain edema were in ipsilateral basal ganglia and peaked at 3 days, which is consistent with a previous study that showed the progression of brain edema after ICH in experimental ICH models, then declines slowly (Xi et al., 2006) . Thus, our results in this study characterized the progression of brain edema and consolidated that the collagenase-induced ICH model is a proper model to test the interventional effects of Mino.
DKK1 is a natural controller of Wnt/β-catenin signaling (Logan and Nusse, 2004) . Inhibition of DKK1 leads to the activation of Wnt pathway and the transcription of downstream target genes (Noelanders and Vleminckx, 2016) . The canonical Wnt/β-catenin signaling is a key regulator of the BBB and critical for stabilization of brain endothelial tight junctions (Artus et al., 2014; Liebner et al., 2008) . Here we found that Mino reduces the expression of DKK1 and enhances Wnt/β-catenin in ICH model and cultured rat microglia, suggesting DKK1 is a target or at least one of the targets employed by Mino to reduce the edema of BBB. Moreover, these findings are consistent with our previous study (Li et al., 2017a) , which showed that DKK1 deficiency reduced brain edema and BBB disruption. Although the same ICH animal model was used and similar phenotypes were tested in both studies, our current study for the first time delineates the signaling pathway that minocycline mediated to protect against brain damage (Fig. 8) . Moreover, our findings in this study consolidated the effects of Mino on the expression of DKK1 (Fig. 5 ) in microglia cells, suggesting Mino could suppress neuroinflammatory responses through controlling the expression of DKK1.
There are multiple mechanisms reported to explain the protective effects of Mino against the brain damage. The most common opinion is that Mino could function as an efficient iron chelator to reduce excessive cerebral iron and thus improve functional recovery (Luo et al., 2017; Xi, Strahle, Hua, and Keep, 2014; Zou et al., 2017) . Mino may also inhibit activation of microglia and thus provide neuroprotection (Elewa, Hilali, Hess, Machado, and Fagan, 2006; Klegeris and McGeer, 2000; Tikka and Koistinaho, 2001; Wasserman and Schlichter, 2007a; Yong et al., 2004) . Recent studies reported the inflammatory responses in the local perihematomal area and their deleterious effects on the outcomes of ICH (Illanes et al., 2011; Xue and Del Bigio, 2000) . Therefore, the regulation of inflammation, both intensity and duration, could be an important way for Mino to protect against the brain damage in ICH. Our results showed that Mino decreases the magnitude of inflammatory mediators and MMP-9 in LPS-stimulated rat microglia, which is consistent with the previous findings in other studies (Orsucci, Calsolaro, Mancuso, and Siciliano, 2009; Yong et al., 2004) , suggesting that Mino could function through controlling inflammation. Considering the anti-inflammatory properties of β-catenin in the development of inflammation (Duan et al., 2007; Wang et al., 2016; Zolezzi and Inestrosa, 2017) , Mino-mediated activation of Wnt/β-catenin signaling could be a key in the protection of ICH. However, our findings didn't exclude the possibility that other molecular mechanisms are also involved in the protective effect of minocycline. It is more possible for minocycline to use a "multiple-to-multiple" signaling paradigm rather than "single-to-single" in this process. Moreover, combination of the minocycline with siRNA of DKK1 leads to an additive effect on the BBB integrity, occludin expression, and Wnt signaling also suggested the existence of synergistic mechanisms. Thus, further study to elucidate underlying mechanisms of minocycline would provide more precise interventional targets for the control of edema and further improvement of ICH. Immunoblots were stripped and re-probed with an antibody to GAPDH to ensure equal protein loading. "*" and "***" represent significant differences at P < 0.05 and P < 0.001, respectively. Results represent the mean ± SEM of three separate experiments. The expression of DKK1 around the hematoma after siDKK1 administration. Protein expression was normalized to GAPDH and expressed as ratio of sham (n = 3 for each group; *P < 0.05, **P < 0.01). (B) The expression of Wnt1, β-catenin and Occludin around the hematoma after intracerebral hemorrhage. Protein expression was normalized to GAPDH and expressed as ratio of sham (n = 3 for each group; *P < 0.05, ** P < 0.01, ***P < 0.001). (C) Blood-brain permeability was evaluated using Evan's blue staining (n = 6 for each group; *P < 0.05, **P < 0.01). (D) Brain water content in contralateral cortex (Contra-Cortex), ipsilateral cortex (Ipsi-Cortex), contralateral basal ganglia (Contra-Basal Ganglia), ipsilateral basal ganglia (Ipsi-Basal Ganglia), and the cerebellum (Cerebellum) (n = 6 for each group; **P < 0.01, ***P < 0.001). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) DKK1expression in the ipsilateral basal ganglia significantly increased after ICH. In the present study, fluorescence staining with multiple probes showed that DKK1 is co-localized with CD11c + positive cells around the hematoma. Since CD11c is expressed on multiple types of myeloid-derived inflammatory cells including activated microglia, Mino induced reduction of DKK1 could mainly occur in the microglia in ICH, which was also confirmed by the cultured rat microglia. Recent study reported that Mino reduced DKK1 expression after hepatic ischemia/reperfusion injury (Li et al., 2015) , suggesting Mino-induced alteration of DKK1 could occur in multiple tissues. Thus, more studies to examine the effects of Mino on the expression of DKK1 in other models will validate our results and highlight the protective function of DKK1-Wnt signaling in ICH.
Taken together, our findings have demonstrated for the first time that Mino inhibits DKK1 expression in perihematomal tissue and microglia, leading to the activation of Wnt signaling, the decrease of inflammatory responses, and ultimately the improvement of brain damage in ICH.
These findings not only consolidated the protective effects of Mino, but also provided novel insights on the understanding the underlying molecular mechanisms, which will aid to develop more precise therapeutic drugs in the treatment of brain injury and alleviate the outcomes of ICH.
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